T. I. Ionova, T. P. Nikitina, K. A. Kurbatova, A.Y. Rodionova

Quality of life and health utility index in patients with type 2 diabetes mellitus receiving oral hypoglycemic therapy

The aim of study was to evaluate quality of life in patients with type 2 diabetes mellitus (DM2) receiving different oral hypoglycemic therapy as well as to determine health utility Ut for each treatment modality. In the whole, 229 patients with DM2 (mean age – 61.3±9.5 years, 68.1% females) receiving oral hypoglycemic therapy (vildagliptin plus metformin/GalvusMet, n=104; sulphonylureas plus metformin, n=125) were involved in the study.

Mean duration of the disease was 5.9±4.1 years, mean level of HbA1с – 6.9%±0.8%, late complications were revealed in 27.5% of patients, chronical comorbidities – in 64.6% of patients. All the patients completed SF-36 questionnaire. The health utility Ut was calculated for each patient by means of SF-6D questionnaire.

The SF-6D utility index was obtained on the basis of the SF-36. It has been shown that patients receiving vildagliptin plus metformin/GalvusMet therapy had higher quality of life parameters by the majority of SF-36 scales as well as by Integral QoL Index as compared to those receiving sulphonylureas plus metformin therapy.

The mean Ut for patients on vildagliptin plus metformin/GalvusMet was higher as compared to mean Ut for patients on sulphonylureas plus metforminThe obtained values of health utility Ut may be used to calculate QALYs within cost-utility analysis to estimate treatment outcomes in DM2 patients receiving oral hypoglycemic therapy.